Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction: Although early use of broad-spectrum antimicrobials in critically ill patients may increase antimicrobial adequacy, uncontrolled use of these agents may select for more-resistant organisms. This study investigated the effects of early use of broad-spectrum antimicrobials in critically ill patients with hospital-acquired pneumonia. Methods: We compared the early use of broad-spectrum antimicrobials plus subsequent de-escalation (DE) with conventional antimicrobial treatment (non-de-escalation, NDE) in critically ill patients with hospital-acquired pneumonia (HAP). This open-label, randomized clinical trial was performed in patients in a tertiary-care center medical intensive care unit (MICU) in Korea. Patients (n = 54) randomized to the DE group received initial imipenem/cilastatin plus vancomycin with subsequent de-escalation according to culture results, whereas patients randomized to the NDE group (n = 55) received noncarbapenem, nonvancomycin empiric antimicrobials. Results: Between November 2004 and October 2006, 109 MICU patients with HAP were enrolled. Initial antimicrobial adequacy was significantly higher in the DE than in the NDE group for Gram-positive organisms (100% versus 14.3%; P < 0.001), but not for Gram-negative organisms (64.3% versus 85.7%; P = 0.190). Mean intensive care unit (ICU) stay, and 14-day, 28-day, and overall mortality rates did not differ in the two groups. Among culture-positive patients, mortality from methicillin-resistant Staphylococcus aureus (MRSA) pneumonia was higher in the DE group, even after early administration of vancomycin. Multidrug-resistant organisms, especially MRSA, were more likely to emerge in the DE group (adjusted hazard ratio for emergence of MRSA, 3.84; 95% confidence interval, 1.06 to 13.91). Conclusions: The therapeutic advantage of early administration of broad-spectrum antimicrobials, especially with vancomycin, was not evident in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805 · cited 1×
“Previous studies, however, have reported that DE was associated with higher antimicrobial adequacy and more favorable outcomes [6,25-27].”
ResultIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 1×
“Although inadequate initial therapy may increase mortality rates [7], the frequent use of carbapenem plus vancomycin predisposes to the emergence of MDR organisms.”
Background
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Antibiotic stewardship in the intensive care unit
Luyt, C.-E., Bréchot, N., Trouillet, J.-L., & Chastre, J. (2014) · Critical Care · doi:10.1186/s13054-014-0480-6 · Cited by 388
Pugh, R., Grant, C., Cooke, R. P., & Dempsey, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007577.pub3 · Cited by 289
Tabah, A., Cotta, M. O., Garnacho-Montero, J., Schouten, J., Roberts, J. A., Lipman, J., Tacey, M., Timsit, J.-F., Leone, M., Zahar, J. R., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1199 · Cited by 220
“Kim et al [18] 2012 ADE group: imipenem + vancomycin; non-ADE group: empiric antimicrobials according to national guidelines for nosocomial pneumonia Yes Yes No Yes Not ranked 3 to 5th d”
BackgroundMethodTabah, A., Bassetti, M., Kollef, M. H., Zahar, J.-R., Paiva, J.-A., Timsit, J.-F., Roberts, J. A., Schouten, J., Giamarellou, H., Rello, J., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05866-w · Cited by 191
Metadata
- Authors
- Kim, J. W., Chung, J., Choi, S.-H., Jang, H. J., Hong, S.-B., Lim, C.-M., & Koh, Y.
- Venue
- Critical Care
- Published
- 2012-02-15
- Volume
- 16
- Issue
- 1
- Pages
- R28-R28
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2096914175
- Cited by
- 72
- References
- 2
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. https://app.cochat.ai/papers/10.1186/cc11197
- The paper
- Kim, J. W., Chung, J., Choi, S.-H., Jang, H. J., Hong, S.-B., Lim, C.-M., & Koh, Y. (2012). Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Critical Care. https://doi.org/10.1186/cc11197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.